630 - Efficacy comparison of targeted systemic monotherapies including lebrikizumab for moderate-to-severe atopic dermatitis: a network meta-analysis.

MLA

Silverberg, Jonathan I., et al. “630 - Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A Network Meta-Analysis.” British Journal of Dermatology, vol. 191, Aug. 2024, pp. 1–2. EBSCOhost, https://doi.org/10.1093/bjd/ljae266.014.

APA

Silverberg, J. I., Bieber, T., Paller, A., Beck, L. A., Kamata, M., Puig, L., Wiseman, M., Ezzedine, K., Foley, P., Johansson, E., Dossenbach, M., Akmaz, B., Casillas, M., Karlsson, A., & Chovatiya, R. (2024). 630 - Efficacy comparison of targeted systemic monotherapies including lebrikizumab for moderate-to-severe atopic dermatitis: a network meta-analysis. British Journal of Dermatology, 191, 1–2. https://doi.org/10.1093/bjd/ljae266.014

Chicago

Silverberg, Jonathan I, Thomas Bieber, Amy Paller, Lisa A Beck, Masahiro Kamata, Luis Puig, Marni Wiseman, et al. 2024. “630 - Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A Network Meta-Analysis.” British Journal of Dermatology 191 (August): 1–2. doi:10.1093/bjd/ljae266.014.